BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34304770)

  • 21. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.
    Stein H; Foss HD; Dürkop H; Marafioti T; Delsol G; Pulford K; Pileri S; Falini B
    Blood; 2000 Dec; 96(12):3681-95. PubMed ID: 11090048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.
    ten Berge RL; Snijdewint FG; von Mensdorff-Pouilly S; Poort-Keesom RJ; Oudejans JJ; Meijer JW; Willemze R; Hilgers J; Meijer CJ
    J Clin Pathol; 2001 Dec; 54(12):933-9. PubMed ID: 11729213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
    ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
    Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
    Barth M; Xavier AC; Armenian S; Audino AN; Blazin L; Bloom D; Chung J; Davies K; Ding H; Ford JB; Galardy PJ; Hanna R; Hayashi R; Lee-Miller C; Machnitz AJ; Maloney KW; Marks L; Martin PL; McCall D; Pacheco M; Reilly AF; Roshal M; Song S; Weinstein J; Zarnegar-Lumley S; McMillian N; Schonfeld R; Sundar H
    J Natl Compr Canc Netw; 2022 Nov; 20(11):1267-1275. PubMed ID: 36351334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification.
    Monabati A; Safaei A; Noori S; Mokhtari M; Vahedi A
    Ann Hematol; 2016 Mar; 95(4):613-8. PubMed ID: 26754635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.
    Au-Yeung RKH; Arias Padilla L; Zimmermann M; Oschlies I; Siebert R; Woessmann W; Burkhardt B; Klapper W
    Br J Haematol; 2020 Sep; 190(5):753-763. PubMed ID: 32239695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
    Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
    Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
    J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Hodgkin Lymphoma in Children.
    Sandlund JT
    Curr Hematol Malig Rep; 2015 Sep; 10(3):237-43. PubMed ID: 26174528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective.
    Dunleavy K; Gross TG
    Blood; 2018 Jul; 132(4):369-375. PubMed ID: 29895666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the spectrum of T-cell lymphomas with regulatory phenotype.
    Ferreira CR; Zhao S; Sahoo MK; Pinsky B; Weber J; Lage LAPC; Pereira J; Zerbini MCN; Natkunam Y
    Hum Pathol; 2018 Oct; 80():138-144. PubMed ID: 29898383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of 2016 WHO classification in the diagnosis of paediatric high-grade
    Zhang L; Brown LE; Bowen LM; McCarthy LC; Cooley LD; Repnikova E; Gener MA; Garola R; August KJ; Hays JA; Zwick DL; Li W
    J Clin Pathol; 2020 Sep; 73(9):563-570. PubMed ID: 31964683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials.
    Seidemann K; Tiemann M; Henze G; Sauerbrey A; Müller S; Reiter A
    Med Pediatr Oncol; 1999 Dec; 33(6):536-44. PubMed ID: 10573576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.
    Kagami Y; Suzuki R; Taji H; Yatabe Y; Takeuchi T; Maeda S; Kondo E; Kojima M; Motoori T; Mizoguchi Y; Okamoto M; Ohnishi K; Yamabe H; Seto M; Ogura M; Koshikawa T; Takahashi T; Kurita S; Morishima Y; Suchi T; Nakamura S
    Am J Surg Pathol; 1999 Oct; 23(10):1184-200. PubMed ID: 10524519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular abnormalities in lymphomas].
    Delsol G
    Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.
    Sakarou M; Eisele L; Dührsen U; Hüttmann A
    Eur J Haematol; 2019 Mar; 102(3):241-250. PubMed ID: 30471148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide.
    Wen KW; Fakhri B; Menke J; Ruiz-Cordero R; Gill RM; Ohgami RS
    Ann Diagn Pathol; 2020 Jun; 46():151534. PubMed ID: 32473554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extranodal non-hodgkin lymphomas of the oral cavity and maxillofacial region: a clinical study of 58 cases and review of the literature.
    Triantafillidou K; Dimitrakopoulos J; Iordanidis F; Gkagkalis A
    J Oral Maxillofac Surg; 2012 Dec; 70(12):2776-85. PubMed ID: 22494508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.